Recently, a clinical study on 180 HER2-positive patients under trastuzumab treatment explored the relationship between domain-specific HER2 expression of the tumor on IHC and the benefit of treatment for the patient in terms of disease-free survival (DFS). This evidence concerns the gene ERBB2 and neoplasm.